Concordance of Immunohistochemistry and In Situ Hybridization for Assessment of Human Epidermal Growth Factor Receptor 2 Status in Breast Cancer Patients in Sawanpracharak Hospital
Keywords:
HER2 status, Immunohistochemistry, In situ hybridization, concordanceAbstract
Objective : To investigate the concordance between immunohistochemistry (IHC) and in situ hybridization (ISH) for HER2 status and to evaluate the correlation in clinicopathological characteristics in breast cancer patients.
Methods : This study was a retrospective study enrolled breast cancer patients of Sawanpracharak Hospital who had IHC (2+ and 3+) and ISH results between January 2018 to October 2021. The HER2 status of invasive ductal breast cancer from 128 cases was determined. The Concordance between IHC and ISH and the correlation between HER2 ISH and their clinicopathological characteristics were evaluated using a rank sum test and exact probability at a 95% confidence interval.
Results : Total concordance was 79.7% with a Kappa coefficient of 0.485 (p<0.001). The concordance was detected at 97.4% with IHC 3+ and 52.9% with IHC 2+. There was no significant correlation between HER2, ISH, and the patient’s age, tumor size, tumor side, or histologic grade
Conclusion : Our study showed a high concordance rate between IHC 3+ and ISH. Regarding the results, IHC 3+ breast cancer patients could be treated with targeted therapy without ISH confirmation to decrease waiting time and cost. Further ISH study should be limited to IHC 2+.
Keywords : HER2 status, Immunohistochemistry, In situ hybridization, concordance
References
Global Cancer Observatory. Estimated cancer incidence, mortality and prevalence worldwide in 2020[internet]. 2020 [cited 2022 Jun 15]. Available from: http//globocan.iarc.fr/factsheet.asp
Jedpiyawongse A, Sakapiboonnan A, Tanasitthichai S. p95HER2 and Breast Cancer. Thai Cancer J 2017; 37(3):114-22.
Pongthong W, Aiamanan M. Nurses role in preventing cardiotoxicity from Trastuzumab drug in HER2 breast cancer patients. TJN 2020; 69(2):56-65.
Fleiss JL, Levin B and Paik MC. Statistical Methods for Rates and Proportions, Third Edition. New Jersey: John Wiley & Sonc; 2003.
Zhao B, Wang Y, Xu H. Concordance of immunohistochemistry and fluorescence in situ hybridization for assessment of HER2 status in breast cancer patients in Xinjiang autonomous region, China. Int J Clin Exp Pathol 2017; 10(10):10459-66.
Bogdanovska-Todorovska M, Kostadinova-Kunovska S, Jovanovik R, Krsteska B, Kondov G, Kondov B, et al. Correlation of Immunohistochemistry and Fluorescence in Situ Hybridization for HER2 Assessment in Breast Cancer Patients: Single Centre Experience. Maced J Med Sci 2018; 6(4):593-9.
Ruan S, Liu Y, Tang X, Yang Z, Huang J, Li X, et al. HER2 status and its clinicopathologic significance in breast cancer in patients from southwest China: re-evaluation of correlation between results from FISH and IHC. Int J Clin Exp Pathol 2017; 10(7):7270-6.
Payandeh M, Sadeghi M, Sadeghi E, Janbakhsh A. Is there any concordance between of IHC with FISH in HER2-positive breast cancer patients?. Int J Hematol Oncol Stem Cell Res 2017; 11(1):43-8.
Bahreini F, Soltanian AR, Mehdipour P. A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer. Breast cancer 2015; 22(6):615-25.
Thambamroong T. The Concordance between IHC and ISH for HER-2 testing in breast cancer in Nakhon Pathom Hospital, Thailand, based on the ASCO/CAP 2018 guidelines:a retrospective study. Ecancermedicalscience. 2022; 16:1370.
Pala EE, Bayol U, Ozguzer A, Kucuk U, Yildiz C, Sezer O. Problems In Determining Her2 Status In Breast Carcinoma. J Breast Health 2015; 11:10-6.
Tas EO, Pala E, Ercan I, Sag S. Investigating impact of polysomy 17 in breast cancer patients with HER2 amplification through meta-analysis. Turkish J Bio 2019; 44(4):411-6.
Mansfield AS, Sukov WR, Eckel-Passow JE, Yuta S, Walsh FJ, Lonzo M, et al. Comparison of Fluorescence In Situ Hybridization (FISH) and Dual-ISH (DISH) in Determination of HER2 Status in Breast Cancer. Am J Clin Pathol 2013; 139:144-50.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Region 3 Medical and Public Health Journal - วารสารวิชาการแพทย์และสาธารณสุข เขตสุขภาพที่ 3
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
